Navigation Links
The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System

Key words: CXCR2 • GPCR • receptor binding assay • LEADseeker • SPA Imaging Beads


Chemo-attractant cytokines (chemokines) are low molecular weight, pro-inflammatory cytokines with potent leukocyte activation and/or chemotactic activity in vivo (1). Chemokines are classified into four families (CXC, CC, C, and CXC3) based on the number and sequential relationship of the first two of four conserved cysteine residues. They induce their biological effect by binding to chemokine receptors that belong to the superfamily of G protein-coupled seven-transmembrane domain receptors (2).

The CXC chemokines are pivotal mediators that activate or inhibit angiogenesis by interacting with cognate receptors expressed by endothelial cells (3). CXCR2 is a major chemokine receptor expressed in neutrophils and binds chemokines with a Glu-Leu-Arg (ELR) sequence in the amino terminus; IL-8, GRO-α, GRO-β, GRO-γ, NAP-2, ENA-78, and GCP-2 (4).

This application note describes a 384-well CXCR2 chemokine receptor-binding assay which has been developed using the LEADseeker™ Multimodality Imaging System.


Materials
Products used
LEADseeker Multimodality Imaging System 18-1140-71

Wheat Germ Agglutinin (WGA) PS SPA RPNQ0260
Imaging Beads

[125I]GRO-a IM305


Other materials required
Human recombinant CXCR2 receptor membrane preparation (Euroscreen ES-145-M)

Human recombinant IL-8 (Sigma 123K0714)

Human recombinant GRO-α(Sigma G0657)

Costar™ solid white 384-well NBS™ coated assay plate (Corning 3652)

EDTA-free protease inhibitor cocktail tablets (Roche 1873580)

Buffer: 25-mM HEPES pH 7.4, 5-mM MgCl2, 1-mM CaCl2, 0.2% (w/v) BSA, protease inhibitors (one tablet per 50-ml buffer).
Note: that BSA and protease inhibitors were added freshly on the day of use.

GraphPad Prism™ software (GraphPad Software)


Protocol
1. Human recombinant CXCR2 receptor membrane preparation was used in conjunction with [125I]GRO-αligand and WGA PS SPA Imaging Beads. Non-specific binding (NSB) was determined in the presence of 125-nM IL-8. The standard assay format was as follows

2. Reagents were added in the following order: Buffer or DMSO solution, unlabeled ligand (NSB wells), labeled ligand, premixed bead, and membrane. Total assay volume was 40 µl

3. Diluted membrane and bead were premixed at room temperature immediately prior to assay addition.

4. Wells contained 10 µl of 1.48-nM [125I]GRO-α(final concentration 0.37 nM) unless otherwise stated. Wells also contained 0.1 mg of beads and 1.2 µg of membrane, which were added together in a 20-µl volume.

5. NSB wells contained 10 µl of 0.5-µM IL-8 (final concentration 0.125 µM) in addition to the above.

6. For DMSO tolerance studies, DMSO was diluted in binding buffer to give final concentrations per well as shown in the results.

7. Plates were sealed and incubated in darkness for 8 h at room temperature (20–25 ºC) unless otherwise stated.

8. Following incubation, plates were imaged on the LEADseeker Multimodality Imaging System for 3 min with quasi-coincident averaging and 3 ×3 binning.


Results

Kd determination
Saturation binding was performed with dilutions of [125I]GRO-αto give a range of concentrations from 2.5 to 2000 pM in the wells. Figure 1 shows the saturation curve that was fitted using non-linear regression with the data analysis software package GraphPad Prism v4.0. A Kd value of 383 pM (95% confidence intervals 318 to 447 pM) was estimated directly from the curve and Bmax was determined at 6 pmol/mg of protein.

DMSO tolerance
Dilutions of DMSO were prepared in assay buffer to give a range of concentrations from 2% (v/v) to 25% (v/v) in the wells. From the results shown in figure 2 it can be seen that the assay was tolerant to DMSO up to a final concentration of 12.5% (v/v)

IC50 determination
Competitive binding of 0.37-nM [125I]GRO-αwith unlabeled IL-8 and GRO-αwas assessed and the IC50 values calculated as shown in Figure 3. DMSO was included at an assay concentration of 2.5% (v/v). Final concentrations in the well for unlabeled GRO-αwere 0.03 to 440 nM, and for unlabeled IL-8, 0.03 to 500 nM.

The IC50 value for GRO-αwas determined to be 2 nM (95% confidence interval range 1.7 to 2.3 nM) and the Ki value was 1.02 nM (95% confidence intervals 0.87 to 1.19 nM). The IC50 value for IL-8 was 11 nM (95% confidence interval range 10 to 12 nM) and the Ki was 5.68 nM (95% confidence intervals 5.14 to 6.27 nM).

Time course
A time course was performed using standard reagent concentrations as detailed in the protocol and DMSO included at an assay concentration of 2.5% (v/v). Readings were taken over an increased incubation time of 18 h. The assay reached equilibrium after approximately 7 h and was stable for at least a further 5 h as demonstrated by the results shown in Figure 4.

Zanalysis
Finally, a Z′analysis was performed using 48 replicate values each for "total" and NSB wells, Z′was determined to be 0.83 (Fig 5), which confirmed the robustness of the assay (5).


Conclusions
The CXCR2 chemokine receptor-binding assay has been successfully miniaturized to a 384-well format using the LEADseeker Multimodality Imaging System and is suitable for adaptation to automated screening formats. The assay is tolerant to DMSO up to a concentration of 12.5% (v/v), robust; achieving a Z′value of 0.83, and has a stability window of at least 5 h.


References
1. Rossi, D. and Zlotnik, A. Annual Review Immunology 18, 217–242 (2000).

2. Premack, B. A. and Schall, T. J. Nature Medicine 2, 1174–1178 (1996).

3. Addison, C. L. et al. Journal of Immunology, 165, 5269–5277 (2000).

4. Clark-Lewis, I. et al. Journal Biological Chemistry 278 (1), 289–295 (2003).

5. Zhang, J. et al. Journal Biomolecular Screening 4 (2), 67–73 (1999).



back to top
'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
2. The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System
3. The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System
4. The development of a somatostatin sst4 receptor-binding assay using the LEADseeker Multimodality Imaging System
5. The development of a serotonin 5-HT2C receptor-binding assay using the LEADseeker Multimodality Imaging System
6. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
7. LiquiChip Kits for bead-based cytokine and kinase assays
8. Quality control of antibodies using the 2100 bioanalyzer and the Protein 200 Plus assay
9. High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system
10. Bio-Plex Cytokine Immunoassays and ELISA: Comparison of Two Methodologies in Testing Samples From Asthmatic and Healthy Children, Rev A
11. Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B
Post Your Comments:
(Date:5/26/2015)... 26, 2015 The University of ... Max Planck Society establishing the Max Planck-University ... center will link two of the world's foremost research ... only the third Max Planck Centre in North America. ... for optics and photonics, was with university and ...
(Date:5/26/2015)... 26, 2015 Innovacyn, a leader ... the human and animal health industries, announced today ... Innovators of Agriculture College Scholarship Award. The scholarship ... exhibits a passionate commitment to the agriculture industry ... year’s winners, Alexis Pedrow from Anderson County Jr/Sr ...
(Date:5/26/2015)... May 26, 2015  Sangamo BioSciences, Inc. (NASDAQ: SGMO ... and CEO, will provide an update on the progress of ... of the company,s business strategy at 1:30pm ET on Monday, ... The conference is being held in New York, ... live and may be accessed via a link on the ...
(Date:5/26/2015)... 26, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... Company,s Annual Meeting of Shareholders for fiscal year ended ... at the Company,s office located in Chengdu, ... AM (local time in Chengdu, China ...
Breaking Biology Technology:Third Max Planck Centre in North America Inaugurated at University of Ottawa 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 3Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 2Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 3Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 3
... a lot of excitement a few years ago following ... could be used to build nanoparticles of a given ... remained out of reach. An international team of researchers ... and Professor Friedrich Simmel of the Technische Universitaet Muenchen ...
... 2012 The Foundation of UMDNJ, an affiliate of ... biomarkers grant through the Bill & Melinda Gates Foundation,s ... seeks to overcome persistent bottlenecks in creating new tools ... With the grant, Dr. David Alland, ...
... United Arab Emirates   is the First Country in ... Allergy Sufferers - Nycomed, a Takeda company, ... in the United Arab Emirates for the treatment of allergic ... adults and adolescents over the age of 12.   ...
Cached Biology Technology:Nano spiral staircases modify light 2Foundation of UMDNJ Receives Grand Challenges Tuberculosis Biomarkers Grant 2Foundation of UMDNJ Receives Grand Challenges Tuberculosis Biomarkers Grant 3Nycomed, a Takeda Company, Launches Omnaris® Nasal Spray in the UAE for the Treatment of Allergic Rhinitis 2Nycomed, a Takeda Company, Launches Omnaris® Nasal Spray in the UAE for the Treatment of Allergic Rhinitis 3Nycomed, a Takeda Company, Launches Omnaris® Nasal Spray in the UAE for the Treatment of Allergic Rhinitis 4
(Date:5/22/2015)... 22, 2015 According to a ... (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), by ... Utilities, Consumer and Home) - Global Forecast to 2020", ... $2.77 Billion in 2015 to $6.19 Billion by 2020, ... 79 market data Tables and   43 Figures spread ...
(Date:5/19/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
(Date:5/14/2015)... NEW YORK , May 14, 2015 ... specializing in identity verification and online remote ... Instructure, a software-as-a-service (SaaS) company and creator ... Shared customers of the two companies will ... Proctortrack in Canvas. As a ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... NEW ORLEANS Three and a half years after ... and sustained use of genetically engineered T cells to ... of Medicine at the University of Pennsylvania and the ... results of studies involving both adults and children with ...
... can have beneficial health effects, scientists have sought to ... A new study by researchers in Wisconsin, Spain, and ... in the body following a period of mindfulness meditation. ... of intensive mindfulness practice in a group of experienced ...
... pulses support the idea that intuition-defying quantum interactions between ... light to fuel their growth. But key details of ... role that quantum physics may play in understanding them ... an Overview Article in the January issue of ...
Cached Biology News:Penn Medicine team reports on study of first 59 leukemia patients who received cell therapy 2Penn Medicine team reports on study of first 59 leukemia patients who received cell therapy 3Penn Medicine team reports on study of first 59 leukemia patients who received cell therapy 4Penn Medicine team reports on study of first 59 leukemia patients who received cell therapy 5Study reveals gene expression changes with meditation 2Study reveals gene expression changes with meditation 3Quantum effects help cells capture light, but the details are obscure 2
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
... TAMRA isomers are predominantly used for labeling ... for labeling peptides and nucleotides because they ... is often required in the conjugation processes. ... for labeling peptides and proteins. 6-TAMRA is ...
anti-Lactate Dehydrogenase...
Mouse monoclonal [6E10] to LAP2 ( Abpromise for all tested applications). entrezGeneID: 7112 SwissProtID: P42166...
Biology Products: